Tumor Vaccines for Solid Tumors

Plain-language summary

This study evaluates a tumor vaccine, together with surgery, radiotherapy, and chemotherapy, for solid tumors. Patients whose intraoperative pathology shows glioma (a type of brain tumor), as well as people with non-tumor conditions (a control group), may take part. It is a non-phase study and is currently enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Huashan Hospital

Intervention

tumor vaccine, Radiotherapy, Chemotherapy, Surgery

Start date

10/1/2023

Estimated completion

10/1/2027

Countries

China

Related genes

Locations

• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

The patients with glioma patients/non-tumor patients (hemorrhagic stroke, ischemic stroke, and traumatic brain injury) in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled:

1. They were no age limit, male and female;
2. The pathological results of frozen section during operation were gliomas or non-tumor;
3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis;
4. Sign informed consent.

Exclusion Criteria:

Patients who meet any of the following criteria will not be included in this study:

1. Participants in other clinical trials;
2. Pregnant women.